SomaLogic And FDA Will Streamline Biosimilar Development

Agreement Aims To Identify Pharmacodynamic Biomarkers For Reference Biologics

 
• By Dean Rudge

Further to the US Food and Drug Administration’s own plans to develop a framework to further the use of pharmacodynamic biomarkers and potentially streamline biosimilar development, the FDA has joined forces with US-based specialist SomaLogic, gaining access to its proprietary technology platform.

Washington, D.C., USA- January 13, 2020: FDA Sign outside their headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
SomaLogic's proteomic strategy, if successful, could reduce the need for comparative clinical studies • Source: Shutterstock

SomaLogic is joining forces with the US Food and Drug Administration’s Division of Applied Regulatory Science to potentially streamline biosimilar development, using the US-based clinical diagnostic firm’s proprietary protein measurement platform technology to identify circulating pharmacodynamic biomarkers for reference biologics.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products